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Abstract
Background: Curing HIV is a new strategic priority for several major AIDS organizations. In step with this new priority,
HIV cure research and related programs are advancing in low, middle, and high-income country settings. This HIV cure
momentum may influence existing HIV programs and research priorities.
Discussion: Despite the early stage of ongoing HIV cure efforts, these changes have directly influenced HIV research
funding priorities, pilot programs, and HIV messaging. The building momentum to cure HIV infection may synergize
with strategic priorities to better identify adults and infants with very early HIV infection. Although HIV cure represents
a new goal, many existing programs and research techniques can be repurposed towards an HIV cure. HIV messages
focused on engaging communities towards an HIV cure need to be careful to promote ARV adherence and retention
within the HIV continuum of care.
Summary: An increased emphasis within the AIDS field on finding an HIV cure has several important implications.
Strengthening connections between HIV cure research and other areas of HIV research may help to catalyze research
and facilitate implementation in the future.
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Background
HIV cure research and related programs are accelerating
around the world. This new priority developed over the
last five years because of an increased understanding of
the long-term side effects of lifelong antiretroviral ther-
apy (ART), the public health challenges of current strat-
egies, and basic science advances regarding HIV latency
[1]. The goal of curing HIV infection is a strategic priority
for the National Institutes of Health National Institute for
Allergy and Infectious Diseases [2], the International AIDS
Society [1], and other organizations. There are over 100
ongoing HIV cure research studies underway around the
world [3].
Although the field of HIV cure is still in its infancy and
many decisions about cure efforts or pilot programs have
not been centrally organized, there are already important
implications of expanding HIV cure momentum [4]. The
purpose of this article is to describe these implications
and to suggest ways that pilot programs could maximally
synergize with existing research and programs. We exam-
ine how HIV cure programs, especially research, have
started to gradually influence funding priorities, pilot pro-
grams for very early HIV detection, and HIV messaging.
Discussion
The most substantial implication of the increased em-
phasis of the AIDS field on finding a cure for HIV is chan-
ging HIV research priorities. The International AIDS
Society HIV cure resources tracking group estimated that
157.9 million USD was invested in HIV cure research in
2014 [5]. These investments from the public sector (139.9
USD) and philanthropies (17.0 million USD) are likely an
underestimate because they did not capture growing pri-
vate sector contributions. A range of public sector funding
agencies in high-income countries have prioritized HIV
cure research, including the United States National Insti-
tutes of Health [2, 6], the Medical Research Council, the
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French National Agency for AIDS Research, and the
Canadian Institutes of Health Research [7]. In addition
to high-income country support, there have been spe-
cial programs to support HIV cure research in China
[8], Thailand [9], and Cuba [10]. The National Insti-
tutes of Health in the United States has been the sin-
gle largest funder of HIV cure research to date,
accounting for 72 % of the 2014 research funds [5].
The American Foundation for AIDS Research an-
nounced a total of 100 million USD in grants to sup-
port HIV cure research [11]. The University of North
Carolina at Chapel Hill and GlaxoSmithKline recently
formed a new public-private partnership to cure HIV,
supported by 20 million dollars from GlaxoSmithKline
over the course of 4 years [12].
The new emphasis on HIV cure within broader HIV
funding priorities raises an important question about
the relationship between HIV cure and other HIV re-
search priorities. The International AIDS Society “To-
wards a Cure” initiative has explicitly stated that the
global HIV response should not divert research funding
from other areas of HIV research towards cure, instead
arguing for greater HIV cure resources [5]. In addition
to greater resources for HIV cure research, there is a
need for integrative research that crosses disciplinary
boundaries [4] and brings together HIV cure and other
existing HIV priorities.
Another important policy implication of the HIV cure
momentum is enhanced detection of adults and adoles-
cents with acute or very early HIV infection. The first
few weeks or months after infection, but prior to sero-
conversion, constitute the period of acute HIV infection
[13]. We define very early HIV infection to include the
6 months following viral acquisition. Adults and adoles-
cents diagnosed and treated during very early HIV in-
fection are critical for HIV cure research [14]. Such
individuals are important because they likely have
smaller reservoirs [14], decreased viral replication [15]
and genetic diversity [16] sustained T-cell and B-cell
function [17, 18], better immune restoration potential,
lack of extended inflammatory responses and comor-
bidities associated with chronic HIV infection [19], and
no or limited previous exposure to antiretrovirals
(ARVs). As a result, individuals with very early HIV in-
fection would likely be easier to cure and recruited for
enrollment in HIV cure research studies. Yet the imple-
mentation of testing programs to identify very early
HIV infections has been challenging [20]. High cost (es-
pecially for small laboratories), logistical problems, and
the brevity of very early HIV infection further compli-
cate the detection of this phase of HIV infection in
many settings. HIV cure strategies for those with very
early HIV infection and those with chronic HIV infec-
tion will both be important.
New HIV cure momentum also provides an opportunity
to synergize and extend existing programs focused on
identifying very early HIV infected individuals. Programs
seeking to increase or improve diagnosis and treatment
during very early infection are driven by both public
health imperatives and concerns for long-term patient
well-being. Public health programs focused on identifying
very early HIV infection have been established because of
the increased risk of onward transmission during very
early infection [21]. Additionally, the advantages of early
diagnosis and suppression of viremia [15, 17–19, 22–24]
add impetus to efforts to introduce and retain these pa-
tients in care. HIV cure-based scientific interest in early
immune response, HIV disease progression, and the estab-
lishment and perpetuation of latent HIV reservoirs may
add further momentum to these efforts if increased num-
bers of very early infected and/or ARV suppressed partici-
pants are required for research participation. Recently, the
Treatment Action Group identified twelve HIV cure re-
search studies around the world already enrolling HIV in-
fected individuals during acute or very early infection [3].
Although the additional momentum created by HIV
cure research is unlikely to overcome logistical problems,
HIV cure may provide another strong reason to enhance
detection of very early HIV infected adults within clinical
trial sites. HIV cure related interest in very early infection
may help to raise awareness about acute HIV infection, its
symptoms, and why early detection and suppression are
important. This would be useful given that many patients
[25] and primary care providers [26] still lack of know-
ledge and awareness about very early infection.
In addition to enhanced detection of very early in-
fected adults and adolescents, HIV cure momentum may
increase the number of neonates discovered with very
early HIV infections. Neonates who acquire HIV infec-
tion from their mothers are another key group for HIV
cure research efforts as demonstrated by the extended
remission of the Mississippi child case [27]. Analogous
to adults and adolescents with early infection, this con-
text provides an opportunity in which there is likely a
smaller reservoir [28] and may be more amenable to
clinical cure research [29]. At the same time, early detec-
tion of neonates with newly acquired HIV infection is
similarly hampered by a range of problems that include
lack of reliable reservoir biomarkers, delays in diagnosis,
and insufficient mechanisms to effectively recruit newly
infected neonates.
Finally, HIV cure has progressively changed how we talk
about HIV in public health messages. Although the re-
sources necessary for implementing HIV control strategies
are substantial, available HIV resources have been stable
or decreasing in many regions [30, 31]. The field of HIV
cure has brought new energy to the HIV field, including
scholars, policymakers, and advocates. Qualitative research
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among HIV-infected individuals has shown that HIV cure
research could spark new hope for healing, decreasing bar-
riers to HIV testing and improving retention through the
care continuum [32]. One HIV cure community engage-
ment project at the University of North Carolina inte-
grated HIV cure alongside testing, prevention, and other
related community HIV campaigns [33]. At the same time,
these messages should be cautious and create realistic
expectations about the timeframe for development of an
HIV cure [34, 35].
Summary
Given the opportunity presented by a growing HIV cure
momentum around the world, we have several recom-
mendations for enabling these policy-program synergies.
First, engaging a wide range of global HIV stakeholders,
especially in low and middle income settings, will be im-
portant for realizing the programmatic synergies articu-
lated above, just as it was in the development of previous
interventions [36]. Policymakers make critical decisions
about implementation and linkages between research and
programs. Second, integrating HIV cure within existing
test and treat priorities will help strengthen existing link-
ages and prevent the development of false dichotomies,
such as that which occurred between HIV prevention and
treatment in the 1990s [37]. Third, optimizing health
systems for very early detection of HIV-infected adults,
adolescents, and neonates would be beneficial for both
individual clinical and public health outcomes. Finally,
the HIV cure global framework requires strengthening
multisectoral linkages between clinicians, policymakers,
advocates, and other stakeholders in order to develop a
comprehensive plan for curing HIV in the future [4].
Conclusion
HIV cure momentum is building in a range of global set-
tings. While this is a new priority, there are several ways
that research towards an HIV cure can strengthen exist-
ing HIV policies and practices.
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